Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBITDA (2023 - 2025)

Historic EBITDA for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$51.1 million.

  • CG Oncology's EBITDA fell 8069.98% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.1 million, marking a year-over-year decrease of 8768.29%. This contributed to the annual value of -$114.7 million for FY2024, which is 10679.54% down from last year.
  • CG Oncology's EBITDA amounted to -$51.1 million in Q3 2025, which was down 8069.98% from -$48.7 million recorded in Q2 2025.
  • CG Oncology's 5-year EBITDA high stood at -$9.7 million for Q1 2023, and its period low was -$51.1 million during Q3 2025.
  • Moreover, its 3-year median value for EBITDA was -$25.9 million (2024), whereas its average is -$28.4 million.
  • As far as peak fluctuations go, CG Oncology's EBITDA plummeted by 13113.88% in 2024, and later crashed by 8069.98% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's EBITDA stood at -$19.4 million in 2023, then plummeted by 96.58% to -$38.0 million in 2024, then crashed by 34.38% to -$51.1 million in 2025.
  • Its EBITDA was -$51.1 million in Q3 2025, compared to -$48.7 million in Q2 2025 and -$42.2 million in Q1 2025.